Sagent Pharmaceuticals Announces the Introduction

SCHAUMBURG, Ill., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT ) today announced the introduction of Oxaliplatin Injection, USP, an antineoplastic agent, now in two liquid presentations. According to IMS, for the 12 months ending July 2014, the US market for Oxaliplatin approximated $102 million. As with all products in Sagent's portfolio, Oxaliplatin features Sagent's PreventIV Measures ^SM packaging and labeling, designed to help reduce the risk of medication errors.

"Jiangsu Hengrui Medicine Co. is a key strategic partnership for Sagent. We are pleased to launch Oxaliplatin Injection, USP, which is the second of many products we plan to launch under this partnership," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board.

About Oxaliplatin Injection, USP

Oxaliplatin Injection, USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor and for treatment of advanced colorectal cancer.

The package insert, available at www.sagentpharma.com , contains the indications, boxed warning, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables.  Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

About Jiangsu Hengrui Medicine Co.

Jiangsu Hengrui Medicine Co., Ltd is an innovative pharmaceutical company and the leading provider of antineoplastic and surgical medications in China. It is also the first Chinese company with injectable products approved by US FDA and EU Authorities. Jiangsu Hengrui Medicine Co., Ltd is listed in the Shanghai Stock Exchange and the stock code is 600276.

INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605